SCHEMBL2017810

SCHEMBL2017810

CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)Oc1ccc(I)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 9/20 0.65
PPARA Q07869 7/20 0.64
PPARG P37231 3/20 0.64
CYP1A2 P05177 3/20 0.64
CYP3A4 P08684 3/20 0.64
MAPT P10636 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
ABCB11 O95342 2/20 0.64
TSHR P16473 2/20 0.64
HTR2A P28223 2/20 0.64
PMP22 Q01453 2/20 0.64
MEN1 O00255 2/20 0.64
CYP2C19 P33261 2/20 0.64
KMT2A Q03164 2/20 0.64
HPGD P15428 2/20 0.64
LMNA P02545 2/20 0.64
MAPK1 P28482 2/20 0.64
USP2 O75604 1/20 0.64
ADORA3 P0DMS8 1/20 0.64
CYP2C9 P11712 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21413783 0.88 ELANE (0.67) ELANEPPARAPPARGCYP1A2CYP3A4
Dulofibrate SCHEMBL2110601 0.85 PPARA (0.68) ELANEPPARAPPARGCYP1A2CYP3A4
SCHEMBL823203 0.83 PPARA (0.70) ELANEPPARAPPARGCYP1A2CYP3A4
SCHEMBL4755814 0.82 PPARA (0.58) ELANEPPARAPPARGCYP1A2CYP3A4
SCHEMBL3744538 0.82 ELANE (0.59) ELANEPPARAPPARGCYP1A2CYP3A4
SCHEMBL4755987 0.81 PPARA (0.72) ELANEPPARAPPARGCYP1A2CYP3A4
SCHEMBL4755982 0.80 PPARA (0.70) ELANEPPARAPPARGCYP1A2CYP3A4
SCHEMBL15674282 0.80 PPARA (0.65) ELANEPPARAPPARGCYP1A2CYP3A4
SCHEMBL10483695 0.79 ELANE (1.00) ELANEPPARAPPARGCYP1A2CYP3A4
SCHEMBL2019433 0.79 ELANE (0.55) ELANEPPARAPPARGCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160225-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-30 US disclosed
US-20110160225-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-30 US disclosed
US-20110160225-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-30 US disclosed
US-20090054450-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed
US-20090054450-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed
US-20090054450-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed
WO-2008157537-A2 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC (US) 2008-12-24 WO disclosed
WO-2008157537-A2 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160225-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS LIPC, PNLIP, LIPA ELANE 879/4885PPARA 93/4885PPARG 104/4885
US-20090054450-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS LIPC, PNLIP, LIPA ELANE 879/4885PPARA 93/4885PPARG 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.